4D Molecular legal chief sells 1,635 shares
FDMT’s chief legal officer exercised options and sold 1,635 shares in a pre-arranged Rule 10b5-1 trade while retaining a sizable remaining option position.
Rhea-AI Filing Summary
4D Molecular Therapeutics, Inc. (FDMT) reported that Chief Legal Officer Scott Bizily exercised options for 1,635 shares of common stock on September 16, 2026 at an exercise price of $4.14 per share and sold the same 1,635 shares at $13.65 per share pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the option exercise, Bizily held 58,066 options directly, and the option award continues to vest monthly from March 6, 2025 through the fourth anniversary of that date.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,635 shares ($16K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Bizily Scott
Role
Chief Legal Officer
Sold
1,635 shs ($22K)
Approx. gross sale proceeds
$22K
Approx. exercise cost
$7K
Approx. pre-tax spread
$16K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 1,635 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,635 | $4.14 | $7K |
| Sale | Common Stock F1 | 1,635 | $13.65 | $22K |
Holdings After Transaction:
Stock Option (Right to Buy) — 58,066 contracts (Direct);
Common Stock — 8,617 shares (Direct)
Footnotes (2)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
- F2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Key Figures
Options Exercised: 1,635 shares
Exercise Price: $4.14 per share
Shares Sold: 1,635 shares
+3 more
6 metrics
Options Exercised
1,635 shares
Options for common stock exercised by Scott Bizily on September 16, 2026
Exercise Price
$4.14 per share
Exercise price of stock options converted into common stock on September 16, 2026
Shares Sold
1,635 shares
Common shares sold by the insider on September 16, 2026
Sale Price
$13.65 per share
Price per share for the insider’s sale of common stock on September 16, 2026
Remaining Options
58,066 options
Stock options held directly by Scott Bizily after the reported exercise
Vesting Schedule
1/48 monthly over 4 years
Option vests monthly from March 6, 2025 until fully vested on fourth anniversary
Key Terms
Rule 10b5-1 trading plan, stock option award, Vesting Commencement Date
3 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option award financial
"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares..."
A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.
Vesting Commencement Date financial
"...on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares..."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did FDMT’s Chief Legal Officer report on September 16, 2026?
Scott Bizily exercised 1,635 options for 4D Molecular Therapeutics common stock at $4.14 per share and sold 1,635 shares at $13.65 per share on September 16, 2026, in a directly held account.
How many FDMT options does the insider hold after this transaction?
After exercising part of his grant, Scott Bizily held 58,066 stock options for 4D Molecular Therapeutics common stock, according to the reported post-transaction derivative holdings.
What prices were involved in the FDMT insider’s option exercise and sale?
The options for 1,635 shares of 4D Molecular Therapeutics common stock were exercised at an exercise price of $4.14 per share, and the resulting 1,635 shares were sold at $13.65 per share on the same date.
How does the FDMT insider’s option grant vest over time?
The stock option award vests as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025, so that 100% of the shares subject to the option are fully vested on the fourth anniversary, while Scott Bizily remains a service provider.
What role does the reporting person hold at 4D Molecular Therapeutics (FDMT)?
The reporting person, Scott Bizily, serves as the Chief Legal Officer of 4D Molecular Therapeutics, Inc., and the reported transactions relate to his equity compensation and trading activity in the company’s common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
